Participant Characteristics | Total N = 25* | Phase 1 N = 10 | Phase II N = 15 |
---|---|---|---|
Doctor(s) seen for lupus1 | |||
Primary care or general doctor | 16 (64.0%) | 7 (70.0%) | 9 (60.0%) |
Lupus specialist or rheumatologist | 25 (100%) | 10 (100%) | 15 (100%) |
Skin doctor or dermatologist | 10 (40.0%) | 4 (40.0%) | 6 (40.0%) |
Kidney doctor or nephrologist | 13 (52.0%) | 6 (60.0%) | 7 (46.7%) |
Treatments or medications taken for lupus2 | |||
Hydroxychloroquine (Plaquenil), Quinacrine (Atabrine), or Chloroquine | 24 (96.0%) | 10 (100%) | 14 (93.3%) |
Azathioprine (Imuran) | 3 (12.0%) | 3 (30.0%) | 0 (0%) |
Mycophenolate Mofetil (CellCept), or Mycophenolic acid or MMF | 17 (68.0%) | 9 (90.0%) | 8 (53.3%) |
Tacrolimus, Sirolimus or Cyclosporin | 4 (16.0%) | 2 (20.0%) | 2 (13.3%) |
Cyclophosphamide (Cytoxan) | 10 (40.0%) | 5 (50.0%) | 5 (33.3%) |
Belimumab (Benlysta) | 8 (32.0%) | 4 (40.0%) | 4 (26.7%) |
Methotrexate | 9 (36.0%) | 2 (20.0%) | 7 (46.7%) |
Prednisone or other steroids | 23 (92.0%) | 10 (100%) | 13 (86.7%) |
Other3 | 8 (32.0%) | 1 (10.0%) | 7 (46.7%) |
Lupus has previously or currently affected kidneys | |||
Yes | 15 (60.0%) | 7 (70.0%) | 8 (53.3%) |
No | 7 (28.0%) | 2 (20.0%) | 5 (33.3%) |
Don’t know | 3 (12.0%) | 1 (10.0%) | 2 (13.3%) |
Currently on dialysis | |||
Yes | 3 (12.0%) | 2 (20%) | 1 (16.7%) |
No | 22 (88.0%) | 8 (80.0%) | 14 (93.3%) |
Experienced being hospitalized for more than 24 h because of a lupus flare | |||
Yes | 19 (76.0%) | 9 (90.0%) | 10 (66.7%) |
No | 6 (24.0%) | 1 (10.0%) | 5 (33.3%) |